Thymosin Alpha-1 Research Overview (also known as TA1, Thymalfasin, Zadaxin)
A naturally occurring 28-amino acid peptide produced by the thymus gland, studied for its role in T-cell maturation, antiviral immune signaling, and inflammatory tone regulation. Has the most developed human research base of any immune-modulating peptide in this category, with clinical applications in hepatitis, cancer support, and immune deficiency research.
"What Is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally occurring in thymosin fraction 5 (TF5), first isolated from bovine thymus by Allan Goldstein in the 1970s. The synthetic version — Thymalfasin (Zadaxin) — is approved in over 35 countries for hepatitis B, hepatitis C (with interferon), and as an adjunct in cancer immunotherapy. It is one of the most extensively studied immunomodulatory peptides with clinical approval.
Mechanism of Action
Tα1 exerts its effects primarily on dendritic cells and T-cells. It promotes dendritic cell maturation and their production of IL-12, IFN-γ, and Type I interferons — cytokines critical for antiviral and antitumor immunity. It increases CD8+ cytotoxic T-cell activity and natural killer cell function, while reducing immunosuppressive regulatory T-cell activity in tumor microenvironments. It activates Toll-like receptor signaling through TLR2 and TLR9, linking it to innate immune pattern recognition.
Clinical Evidence
Multiple RCTs have demonstrated sustained virological response rates significantly higher than placebo in chronic hepatitis B, particularly when combined with interferon. Similar data exist for hepatitis C combination therapy. Cancer immunotherapy studies have shown improved tumor responses in melanoma, lung, and hepatocellular carcinoma. COVID-19 pandemic data demonstrated Tα1's benefit in severe COVID-19, with clinical trials in China documenting significantly reduced mortality in critical patients.
Research Indications
Immunity
Primary Immunodeficiencies
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence.
Vaccine Response Enhancement
Enhances immunogenicity in elderly and immunocompromised patients with improved antibody responses.
HIV/AIDS Immune Support
Restores CD4+ T-cell counts and reduces opportunistic infections with sustained immunological improvement.
Inflammation
Cytokine Storm Mitigation
Reduces pro-inflammatory cytokines by 40-60% while maintaining balanced immune responses.
Chronic Inflammatory Conditions
Modulates inflammatory responses in hepatitis, pancreatitis, and autoimmune conditions.
Recovery
Post-Surgical Immune Recovery
Accelerates immune system recovery following major surgery or chemotherapy through lymphocyte restoration.
Exercise-Induced Immunosuppression
Counters stress-induced immune suppression in athletes and high-stress situations.
Anti-Aging
Thymic Regeneration
Supports age-related thymic decline through hormone replacement therapy in elderly populations.
Immune Senescence Prevention
Delays age-related immune deterioration with improved vaccine responses.
Cellular Health
Antioxidant Enzyme Enhancement
Increases antioxidant enzyme activity providing cellular protection against oxidative damage.
Mitochondrial Function Support
Supports cellular energy metabolism and protects against age-related mitochondrial decline.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard immune support | 1.6 mg | 2x weekly | SubQ |
| Acute conditions (herpes, acute infections) | 1.6 mg | 2x daily × 5 days, then once daily | SubQ or IM |
| Cancer / hepatitis support | 1.6 mg | 2x weekly | SubQ |
| Maintenance / prevention | 1.6 mg | 2x weekly | SubQ |
Timing Note
Best results are observed when doses are spaced evenly throughout the week (e.g. Monday/Thursday). For acute protocols, complete the full 5-day loading course before transitioning to once-daily maintenance. Timing relative to food is not critical — consistency matters most.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
TA-1 enhances T-cell activation and immune surveillance; combining with immunosuppressants directly opposes its mechanism. Requires medical supervision — dose reduction of the immunosuppressant may be needed.
Systemic corticosteroids blunt the T-cell response that TA-1 aims to enhance. Short courses are unlikely to fully cancel benefit, but chronic use significantly reduces efficacy.
Complementary antiviral and immune-modulating mechanisms. TA-1 + IFN-α combinations have been studied in hepatitis B and C with additive clinical outcomes. Combination is used in clinical practice for viral hepatitis.
TA-1 may potentiate vaccine immunogenicity by priming T-cell response. Commonly used in elderly or immunocompromised patients prior to or alongside vaccination to improve antibody titres.
TA-1 is used in oncology settings alongside chemotherapy to restore immune function suppressed by cytotoxic agents. No adverse pharmacokinetic interactions identified; may help reduce infection risk during treatment.
Reported Research Timeline
01Weeks 1–2 (innate immune activation) (reported in cited studies): Thymosin Alpha-1 (Tα1) acts on dendritic cells and NK cells within days of initiation, upregulating TLR signaling, interferons (IFN-α/γ), and innate pattern recognition. This early phase is particularly relevant in chronic infection or post-viral contexts where innate immune dysfunction is a primary driver.
02Weeks 2–6 (T-cell polarization and adaptive response) (reported in cited studies): Tα1 shifts the immune environment from Th2-dominant (immunosuppressive, common in cancer and chronic infection) toward Th1-dominant (pro-immune clearance), increasing CD4+ helper and CD8+ cytotoxic T-cell populations. COVID-19 trials (2021) demonstrated reduced ICU progression in severe cases treated during this window.
03Months 1–3 (adaptive immune reconstitution) (reported in cited studies): Improved vaccine responsiveness, stronger antibody titers, and durable T-cell memory formation have been documented in oncology and hepatitis B/C research contexts. Patients with chronic immune suppression (chemotherapy, HIV, aging) show the most pronounced reconstitution during this phase.
04Long-term (ongoing / cyclical use) (reported in cited studies): Tα1 is used continuously (twice weekly injections) in severe immunodeficiency contexts, or cyclically (4–6 week courses) for periodic immune optimization in anti-aging protocols. Long-term animal data show no adverse effects; the compound does not stimulate indiscriminately, maintaining a self-limiting profile at physiologic doses.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Demonstrated safety profile with adverse event data from over 70,000 patients across 70 clinical trials — one of the most studied immunomodulatory peptides available.
Most common side effect: mild injection-site reactions (redness, brief soreness) — Grade ≤1 in the vast majority of cases.
Contraindicated in organ transplant recipients — TA-1 enhances T-cell activity and may precipitate graft rejection. Do not use without specialist guidance in this population.
Monitor for hypersensitivity reactions with the first dose; subsequent doses are well-tolerated if the first is uneventful.
Not recommended during pregnancy or breastfeeding — no safety data in these populations.
Stop Use and Seek Medical Attention If:
Signs of graft rejection in transplant recipients — seek emergency care immediately
Persistent injection-site reactions or signs of infection (warmth, swelling, discharge)
Unusual immune system hyperactivity (unexplained fever, lymphadenopathy, autoimmune symptoms)
Severe allergic reactions — rash, hives, difficulty breathing, swelling (rare but possible)
Any unexpected or concerning symptoms — consult your healthcare provider immediately
Quality Indicators
Verified Marker
White Lyophilized Powder
Properly freeze-dried powder appears as white, fluffy powder that fills most of the vial bottom. Professional pharmaceutical packaging with sealed rubber stopper.
Verified Marker
Clear Solution After Reconstitution
When mixed with BAC water, solution should be crystal clear with no particles, cloudiness, or precipitation. Any turbidity indicates degradation.
Verified Marker
Proper Pharmaceutical Labeling
Vials should have clear labeling with batch numbers, expiration dates, and filling dosage (mg per vial) clearly marked. Unlabeled vials are a red flag.
Acceptable Range
Minor Powder Compaction
Slight compaction during shipping is acceptable — if powder dissolves completely and solution is clear with gentle swirling, the product is not degraded.
Quality Concern
Discolored or Collapsed Powder
Yellow, brown, or collapsed powder indicates degradation from heat exposure or moisture damage. Do not use.
Quality Concern
Persistent Cloudiness
Solution remains cloudy, contains particles, or shows precipitation after reconstitution — indicates a degraded product. Discard immediately.
Research Citations
- Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Dinetz, E., Lee, E., 2024, Alternative Therapies in Health and Medicine - The Efficacy and Safety of Thymosin α1 for Sepsis (TESTS): Multicentre, Double Blinded, Randomised, Placebo Controlled, Phase 3 Trial
Zhang, L., et al., 2025, BMJ - Thymosin Alpha 1 Alleviates Inflammation and Prevents Infection in Patients with Severe Acute Pancreatitis Through Immune Regulation: A Systematic Review and Meta-Analysis
Tian, M., et al., 2025, Frontiers in Immunology - A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection
Shehadeh, F., et al., 2023, Journal of Infectious Diseases - Thymosin Alpha 1 (Tα1) Reduces the Mortality of Severe COVID-19 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
Liu, Y., et al., 2020, Clinical Infectious Diseases - Thymosin Alpha 1 Restores the Immune Homeostasis in Lymphocytes During Post-Acute Sequelae of SARS-CoV-2 Infection
Romano, M., et al., 2023, Frontiers in Immunology - Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients
Garaci, E., et al., 2021, Frontiers in Immunology - Thymosin Alpha 1: A Comprehensive Review of the Literature
Dominari, A., et al., 2020, World Journal of Virology - The Efficacy of Thymosin Alpha 1 for Severe Sepsis (ETASS): A Multicenter, Single-Blind, Randomized and Controlled Trial
Wu, J., et al., 2013, Critical Care - Immune Modulation with Thymosin Alpha 1 Treatment
King, R., Tuthill, C., 2016, Vitamins and Hormones - Aging and Thymosin Alpha-1
Simonova MA, Ivanov I, Shoshina NS, 2025, Int J Mol Sci - beta-Thymosins
Hannappel E, 2007, Ann N Y Acad Sci - Thymosin alpha 1: A comprehensive review of the literature
Dominari A, Hathaway Iii D, Pandav K, 2020, World J Virol - Thymosin alpha 1 and HIV-1: recent advances and future perspectives
Matteucci C, Grelli S, Balestrieri E, 2017, Future Microbiol - Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549)
Kharazmi-Khorassani J, Asoodeh A, 2019, Environ Toxicol
"
Research Focus
Immune enhancement, Viral infections, Cancer immunotherapy, T-cell activation, Hepatitis treatment
Verified Vendors Carrying Thymosin Alpha-1
Frequently Asked Questions
What should researchers watch for with Thymosin Alpha-1?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Thymosin Alpha-1?
Weeks 1–2 (innate immune activation) (reported in cited studies): Thymosin Alpha-1 (Tα1) acts on dendritic cells and NK cells within days of initiation, upregulating TLR signaling, interferons (IFN-α/γ), and innate pattern recognition. This early phase is particularly relevant in chronic infection or post-viral contexts where innate immune dysfunction is a primary driver.
How is Thymosin Alpha-1 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →